ftInvstr
ALKEM · Healthcare ₹5190.0 +0.07% Mkt Cap ₹61939 Cr undervalued

ALKEM

Healthcare Drug Manufacturers - Specialty & Generic
₹5190.0
+0.07% today · 30d -7.3%
as of 2026-09-04
Price · Daily Candles
“Alkem Laboratories sees Q4 profit climb 1.91% YoY, despite weak technical signals.”
Alkem Laboratories posted a Q4 revenue increase of 10.74% YoY to ₹3737 Cr, with net profit rising 1.91% to ₹653 Cr, demonstrating consistent growth. The company maintains healthy profitability with a TTM profit margin of 16.64% and an annual ROCE of 20.0%, while its stock is currently undervalued by nearly 50% relative to its intrinsic value of ₹8069.53 per share, despite some technical weakness.
BULL CASE
+Q4 revenue increased 10.74% YoY to ₹3737 Cr, with operating profit up 13.93% YoY to ₹971 Cr.
+Annual net profit grew 23.37% YoY to ₹2215 Cr for the period ending March 2025.
+The stock is intrinsically valued at ₹8069.53 per share, indicating a 49.7% margin of safety from its current price of ₹5390.0.
+Promoters hold a significant 51.2% stake, with FIIs increasing their holding by 0.19% QoQ to 10.16% as of March 2026.
+The company boasts strong long-term growth with a 5-year CAGR of 14.03% for net profit and 9.21% for revenue.
BEAR CASE
Net profit growth for Q4 was a modest 1.91% YoY, despite a higher revenue increase.
The stock is down 5.84% over the last six months and is 9.16% off its 52-week high of ₹5933.5.
Technical signals are weak, with MACD in a 'bearish' state at -13.3134 and RSI(14) at a 'neutral' 45.83.
DIIs decreased their stake by 0.14% QoQ to 21.4% in March 2026.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹3740 Cr
+10.95% YoY
NET PROFIT
₹521 Cr
-22.0% YoY
OPM
23.6%
-1.36pp YoY
EPS
₹43.49
PE 27.14
Intrinsic value · DCF ₹6853.40 · Margin of safety +32.1% (undervalued) · FCF yield 2.17%
◇ Sector Position
Alkem Laboratories trades at a TTM PE of 27.14, positioning it lower than Divis Lab (PE 69.81) and Sun Pharma (PE 40.41), with a ROCE of 20.0% which is below industry leaders like Dr. Reddy's (ROCE 27.63).
PEERPEROCE %
ALKEM27.1420.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
64
SCORE / 100
Overall
6-axis composite of the sections below.
Performance POSITIVE 55
Valuation REASONABLE 60
Growth STEADY 64
Profitability HIGH 85
Technicals WEAK 38
Risk LOW 80
Key Stats
TTM PE
27.14
P/B
4.82
52W HIGH
₹5933.5
OFF HIGH
-12.53%
DIV YIELD
0.94%
MKT CAP
₹61939 Cr
◉ Active Signals
MACDBearish-17.7859
RSI(14)Bearish31.87
Near 52W LowBearish2.27
Street Consensus
20 analysts
₹5959.1
mean target
Low ₹4360.0Now ₹5190.0High ₹6913.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold ALKEM and at what entry.

Sign up freeSign in